Revitalizing the Therapeutic Pipeline for C. difficile Infection through Nonantimicrobial and Host-Directed Strategies

Clostridioides difficile infection (CDI) remains a leading cause of healthcare-associated diarrhea, arising largely from antimicrobial-induced displacement of the gut microbiota. Although antimicrobial therapy remains the clinical standard for CDI, high rates of recurrence, the spread of antimicrobial-resistant strains, and inadequate interventions for countering toxin-mediated tissue damage highlight the need for alternative strategies. In this review, we evaluate emerging nonantimicrobial approaches for CDI, focusing on microbial-derived metabolites (including short-chain fatty acids and bile acids), plant-derived phytochemicals, and host-directed therapeutics that modulate inflammatory and neuroimmune pathways. Mechanistic insights into how these strategies mitigate C. difficile pathogenesis are also examined, including roles in attenuating intestinal inflammation and preserving epithelial barrier function. Given the multifactorial nature of CDI, we propose there is a need to advance a new therapeutic framework that integrates narrow-spectrum antimicrobials with nonantimicrobial host-directed modalities. Collectively, this conceptual framework provides a rational foundation for developing next-generation interventions for CDI in an era characterized by multidrug resistance and aging populations with comorbidities that are risk factors for CDI.